HCV-NS3 and IgG-Fc crossreactive IgM in patients with type II mixed cryoglobulinemia and B-cell clonal proliferations

Leukemia

Volumn 20, Issue 6, 2006, Pages 1145-1154

  De Re, V ^a   Sansonno, D ^b   Simula, M P ^a   Caggiari, L ^a   Gasparotto, D ^a   Fabris, M ^c   Tucci, F A ^a,b   Racanelli, V ^b   Talamini, R ^a   Campagnolo, M ^d   Geremia, S ^d   Dammacco, F ^b   De Vita, S ^c  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

^d UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Hepatitis C virus; Lymphoproliferative diseases; Rheumatoid factor

Indexed keywords

B LYMPHOCYTE RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN M; NONSTRUCTURAL PROTEIN 3; RHEUMATOID FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; CRYOGLOBULINEMIA; CRYOPRECIPITATION; EPITOPE MAPPING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNIZATION; IMMUNOCYTOMA; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

EID: 33744495071     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404201     Document Type: Article

References (43)

1. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: Systematic review and meta-analysis. Gastroenterology 2003; 125: 1723-1732.
2. Mele A, Pulsoni A, Bianco E, Musto P, Szklo A, Sanpaolo MG et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: An Italian multicenter case-control study. Blood 2003; 102: 996-999.
3. Dammacco F, Sansonno D, Piccoli C, Racanelli V, D'Amore FP, Lauletta G. The lymphoid system in hepatitis C virus infection: Autoimmunity, mixed cryoglobulinemia, and Overt B-cell malignancy. Semin Liver Dis 2000; 20: 143-157.
4. De Re V, De Vita S, Marzotto A, Rupolo M, Gloghini A, Pivetta B et al. Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. Blood 2000; 96: 3578-3584.
5. De Re V, De Vita S, Marzotto A, Gloghini A, Pivetta B, Gasparotto D et al. Pre-malignant and malignant lymphoproliferations in an HCV-infected type II mixed cryoglobulinemic patient are sequential phases of an antigen-driven pathological process. Int J Cancer 2000; 87: 211-216.
6. Gasparotto D, De Re V, Boiocchi M. Hepatitis C virus, B-cell proliferation and lymphomas. Leuk Lymph 2002; 43: 747-751.
7. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974; 57: 775-788.
8. De Re V, De Vita S, Sansonno D, Gasparotto D, Simula MP, Tucci FA et al. Type II mixed cryoglobulinemia as an oligo rather than a mono B-cell disorder: Evidence by GeneScan and Maldi-Tof analyses. Rheumatology 2006, January 6 (E-pub ahead of print).
9. Sansonno D, Lauletta GF, De Re V, Tucci FA, Gatti P, Racanelli V et al. Intrahepatic B cell clonal expansions and extrahepatic manifestations of chronic HCV infection. Eur J Immunol 2004; 34: 126-136.
10. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 1490-1495.
11. Ferri C, Greco F, Longombardo G, Palla P, Moretti A, Marzo E et al. Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum 1991; 34: 1606-1610.
12. Hussell T, Isaacson PG, Crabtree JE, Spencer J. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 1993; 342: 571-574.
13. De Re V, De Vita S, Gasparotto D, Marzotto A, Carbone A, Ferraccioli G et al. Salivary gland B cell lymphoproliferative disorders in Sjogren's syndrome present a restricted use of antigen receptor gene segments similar to those used by hepatitis C virus-associated non-Hodgkins's lymphomas. Eur J Immunol 2002; 32: 903-910.
14. Bende RJ, Aarts WM, Riedl RG, de Jong D, Pals ST, vas Noesel CJ. Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med 2005; 201: 1229-1241.
15. Kelaidi C, Rollot F, Park S, Tulliez M, Christoforov B, Calmus Y et al. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia 2004; 18: 1711-1716.
16. Levine AM, Shimodaira S, Lai MM. Treatment of HCV-related mantle-cell lymphoma with ribavirin and pegylated interferon Alfa. N Engl J Med 2003; 349: 2078-2079.
17. Emens LA, Sulkowski MS. Regression of splenic lymphoma after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 2168-2170.
18. Mazzaro C, Little D, Pozzato G. Regression of splenic: Lymphoma after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 2168-2170.
19. Hermine O, Lefrere F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 89-94.
20. Guo JQ, You SY, Li L, Zhang YZ, Huang JN, Zhang CY. Construction and high-level expression of a single-chain Fv antibody fragment specific for acidic isoferritin in Escherichia coli. J Biotechnol 2003; 102: 177-189.
21. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia 2003; 17: 2257-2317.
22. C reveals a novel topology of antibody-antigen interaction. Nat Struct Biol 1997; 4: 374-381.
23. Jefferis R, Mageed RA. The specificity and reactivity of rheumatoid factors with human IgG. Monogr Allergy 1989; 26: 45-60.
24. Parker CE, Papac DI, Trojak SK, Tomer KB. Epitope mapping by mass spectrometry: Determination of an epitope on HIV-1 IIIB p26 recognized by a monoclonal antibody. J Immunol 1996; 157: 198-206.
25. Armitage P, Berry G. Statistical Methods in Medical Research. 2nd edn, Blackwell Sc. Publications: Oxford, 1987, 93-140.
26. Young CL, Adamson TC, Vaughan JH, Fox RI. Immunohistologic characterization of synovial membrane lymphocytes in rheumatoid arthritis. Arthritis Rheum 1984; 27: 41-44.
27. Knecht H, Saremaslani P, Hedinger C. Immunohistological findings in Hashimoto's thyroiditis, focal lymphocytic thyroiditis and thyroiditis de Quervain: Comparative study. Virchows Arch Abt A Pathol Anat 1981; 393: 215-220.
28. Monteverde A, Ballare M, Bertoncelli MC, Zigrossi P, Sabattini E, Poggi S et al. Lymphoproliferation in type II mixed cryoglobulinemia. Clin Exp Rheumatol 1995; 13: 141-147.
29. Monti G, Pioltelli P, Saccardo F, Campanini M, Candela M, Cavallero G et al. Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Int Med 2005; 165: 101-105.
30. Quinn ER, Chan CH, Hadlock KG, Foung SK, Flint M, Levy S. The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood 2001; 98: 3745-3749.
31. Alexopoulou A, Dourakis SP. Genetic heterogeneity of hepatitis viruses and its clinical significance. Curr Drug Targets Inflamm Allergy 2005; 4: 47-55.
32. Ou-Yang P, Chiang BL, Hwang LH, Chen YG, Yang PM, Chi WK et al. Characterization of monoclonal antibodies against hepatitis C virus nonstructural protein 3: Different antigenic determinants from human B cells. J Med Virol 1999; 57: 345-350.
33. Puoti M, Zonaro A, Ravaggi A, Marin MG, Castelnuovo F, Cariani E. Hepatitis C virus RNA and antibody response in the clinical course of acute hepatitis C virus infection. Hepatology 1992; 16: 877-881.
34. Sallberg M, Zhang ZX, Chen M, Jin L, Birkett A, Peterson DL et al. Immunogenicity and antigenicity of the ATPase/helicase domain of the hepatitis C virus non-structural 3 protein. J Gen Virol 1996; 77: 2721-2728.
35. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6: 578-582.
36. Day CL, Lauer GM, Robbins GK, McGovern B, Wurcel AG, Gandhi RT et al. Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol 2002; 76: 12584-12595.
37. Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346: 1006-1007.
38. Oppliger IR, Nardella FA, Stone GC, Mannik M. Human rheumatoid factors bear the internal image of the Fc binding region of staphylococcal protein A. J Exp Med 1987; 166: 702-710.
39. Nardella FA, Oppliger IR, Stone GC, Sasso EH, Mannik M, Sjoquist J et al. Fc epitopes for human rheumatoid factors and the relationships of rheumatoid factors to the Fc binding proteins of microorganisms. Scand J Rheumatol Suppl 1988; 75: 190-198.
40. Stone GC, Sjobring U, Bjorck L, Sjoquist J, Barber CV, Nardella FA. The Fc binding site for streptococcal protein G is in the C gamma 2-C gamma 3 interface region of IgG and is related to the sites that bind staphylococcal protein A and human rheumatoid factors. J Immunol 1989; 143: 565-570.
41. Dolganiuc A, Oak S, Kodys K, Golenbock DT, Finberg RW, Kurt-Jones E et al. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 2004; 127: 1513-1524.
42. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416: 603-607.
43. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005; 204: 27-42.